GRI Bio, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
Mailing Address 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
Phone (619) 400-1171
Fiscal Year End 1231
EIN 824369909
Financial Overview
FY2025
$8.67M
Total Assets
$2.66M
Total Liabilities
$8.23M
Cash & Equivalents
$-121.80
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| 8-K Current report of material events | February 4, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 30, 2026 | View on SEC |
| 10-K Annual financial report | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
Annual Reports
10-K January 30, 2026
- GRI Bio is a clinical-stage biotechnology company developing innovative treatments for inflammatory and autoimmune diseases by modulating Natural Killer T (NKT) cells.
- The company achieved positive preclinical data from in vivo studies for its lead NKT cell modulator and completed a successful capital raise.
Material Events
8-K Financial Distress January 21, 2026
High Impact
- GRI Bio, Inc. is a clinical-stage biotechnology company developing novel immune-modulating therapies.
- The reverse stock split aims to regain compliance with Nasdaq's minimum bid price requirement, crucial for maintaining listing, credibility, liquidity, and access to capital.
8-K Financial Distress January 16, 2026
High Impact
- GRI Bio has conditionally regained compliance with Nasdaq's minimum stockholders' equity requirement.
- The company successfully raised approximately $10 million through a private placement, boosting equity above the Nasdaq threshold.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.